Literature DB >> 35895277

Influence of Darolutamide on Cabazitaxel Systemic Exposure.

Stefan A J Buck1, Niels A D Guchelaar2, Peter de Bruijn2, Inge M Ghobadi Moghaddam-Helmantel2, Esther Oomen-de Hoop2, Hans M Westgeest3, Paul Hamberg4, Danielle Mathijssen-van Stein4, Martijn P Lolkema2, Stijn L W Koolen2,5, Ronald de Wit2, Ron H J Mathijssen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35895277     DOI： 10.1007/s40262-022-01159-6

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   5.577


× No keyword cloud information.
  8 in total

1.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Authors:  Ian D Davis; Andrew J Martin; Martin R Stockler; Stephen Begbie; Kim N Chi; Simon Chowdhury; Xanthi Coskinas; Mark Frydenberg; Wendy E Hague; Lisa G Horvath; Anthony M Joshua; Nicola J Lawrence; Gavin Marx; John McCaffrey; Ray McDermott; Margaret McJannett; Scott A North; Francis Parnis; Wendy Parulekar; David W Pook; M Neil Reaume; Shahneen K Sandhu; Alvin Tan; T Hsiang Tan; Alastair Thomson; Emily Tu; Francisco Vera-Badillo; Scott G Williams; Sonia Yip; Alison Y Zhang; Robert R Zielinski; Christopher J Sweeney
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

2.  Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

Authors:  Mario Eisenberger; Anne-Claire Hardy-Bessard; Choung Soo Kim; Lajos Géczi; Daniel Ford; Loïc Mourey; Joan Carles; Phillip Parente; Albert Font; Gabriel Kacso; Mustapha Chadjaa; Wenping Zhang; John Bernard; Johann de Bono
Journal:  J Clin Oncol       Date:  2017-08-15       Impact factor: 44.544

3.  Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Authors:  Karim Fizazi; Stéphanie Foulon; Joan Carles; Guilhem Roubaud; Ray McDermott; Aude Fléchon; Bertrand Tombal; Stéphane Supiot; Dominik Berthold; Philippe Ronchin; Gabriel Kacso; Gwenaëlle Gravis; Fabio Calabro; Jean-François Berdah; Ali Hasbini; Marlon Silva; Antoine Thiery-Vuillemin; Igor Latorzeff; Loïc Mourey; Brigitte Laguerre; Sophie Abadie-Lacourtoisie; Etienne Martin; Claude El Kouri; Anne Escande; Alvar Rosello; Nicolas Magne; Friederike Schlurmann; Frank Priou; Marie-Eve Chand-Fouche; Salvador Villà Freixa; Muhammad Jamaluddin; Isabelle Rieger; Alberto Bossi
Journal:  Lancet       Date:  2022-04-08       Impact factor: 79.321

4.  GPRC5D-Targeted CAR T Cells for Myeloma.

Authors:  Sham Mailankody; Sean M Devlin; Jonathan Landa; Karthik Nath; Claudia Diamonte; Elizabeth J Carstens; Douglas Russo; Romany Auclair; Lisa Fitzgerald; Briana Cadzin; Xiuyan Wang; Devanjan Sikder; Brigitte Senechal; Vladimir P Bermudez; Terence J Purdon; Kinga Hosszu; Devin P McAvoy; Tasmin Farzana; Elena Mead; Jessica A Wilcox; Bianca D Santomasso; Gunjan L Shah; Urvi A Shah; Neha Korde; Alexander Lesokhin; Carlyn R Tan; Malin Hultcrantz; Hani Hassoun; Mikhail Roshal; Filiz Sen; Ahmet Dogan; Ola Landgren; Sergio A Giralt; Jae H Park; Saad Z Usmani; Isabelle Rivière; Renier J Brentjens; Eric L Smith
Journal:  N Engl J Med       Date:  2022-09-29       Impact factor: 176.079

5.  Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.

Authors:  Bodine P S Belderbos; Sander Bins; Roelof W F van Leeuwen; Esther Oomen-de Hoop; Nelly van der Meer; Peter de Bruijn; Paul Hamberg; Esther N M Overkleeft; Wendy M van der Deure; Martijn P Lolkema; Ronald de Wit; Ron H J Mathijssen
Journal:  Clin Cancer Res       Date:  2017-11-17       Impact factor: 12.531

6.  Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.

Authors:  Christian Zurth; Mikko Koskinen; Robert Fricke; Olaf Prien; Timo Korjamo; Kristina Graudenz; Karsten Denner; Michaela Bairlein; Clemens-Jeremias von Bühler; Gary Wilkinson; Hille Gieschen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

Review 7.  Cross-resistance and drug sequence in prostate cancer.

Authors:  Stefan A J Buck; Stijn L W Koolen; Ron H J Mathijssen; Ronald de Wit; Robert J van Soest
Journal:  Drug Resist Updat       Date:  2021-03-18       Impact factor: 18.500
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.